A Double-blind, Randomized, Placebo Controlled, Multicenter, Dose-finding Trial of Ofatumumab in Relapsing Remitting Multiple Sclerosis (RRMS) Patients

Trial Profile

A Double-blind, Randomized, Placebo Controlled, Multicenter, Dose-finding Trial of Ofatumumab in Relapsing Remitting Multiple Sclerosis (RRMS) Patients

Completed
Phase of Trial: Phase II

Latest Information Update: 13 Apr 2017

At a glance

  • Drugs Ofatumumab (Primary)
  • Indications Multiple sclerosis
  • Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 11 Apr 2011 Results from part A of the phase II part of the study presented at the 63rd Annual Meeting of the American Academy of Neurology.
    • 16 Sep 2010 Positive results were announced on 10th September 2010, according to a GlaxoSmithKline and Genmab media release.
    • 16 Sep 2010 Status changed from active, no longer recruiting to completed, based on information in a GlaxoSmithKline and Genmab media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top